Compare ANGI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGI | IFRX |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.4M | 266.6M |
| IPO Year | 2017 | 2017 |
| Metric | ANGI | IFRX |
|---|---|---|
| Price | $6.10 | $2.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $17.00 | $6.25 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1242.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $736,386,000.00 | N/A |
| Revenue This Year | $3.25 | N/A |
| Revenue Next Year | $3.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 47.60 | N/A |
| 52 Week Low | $4.53 | $0.74 |
| 52 Week High | $19.42 | $2.95 |
| Indicator | ANGI | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.90 | 58.51 |
| Support Level | $4.67 | $0.87 |
| Resistance Level | $6.62 | $2.94 |
| Average True Range (ATR) | 0.41 | 0.21 |
| MACD | 0.12 | 0.06 |
| Stochastic Oscillator | 93.29 | 63.64 |
Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.